TuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities researchers at Zacks Small Cap dropped their Q3 2025 EPS estimates for shares of TuHURA Biosciences in a note issued to investors on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings per share of ($0.17) for the quarter, down from their prior forecast of ($0.15). Zacks Small Cap also issued estimates for TuHURA Biosciences' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.63) EPS and FY2026 earnings at ($0.65) EPS.
Separately, HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of TuHURA Biosciences in a report on Friday, May 16th.
Get Our Latest Report on HURA
TuHURA Biosciences Price Performance
TuHURA Biosciences stock traded up $0.08 during trading on Thursday, reaching $2.91. The company had a trading volume of 42,054 shares, compared to its average volume of 242,454. The firm's 50-day simple moving average is $3.76 and its 200 day simple moving average is $4.01. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02).
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC acquired a new position in shares of TuHURA Biosciences during the 4th quarter valued at about $1,084,000. Apollon Wealth Management LLC raised its holdings in TuHURA Biosciences by 86.0% in the 1st quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company's stock valued at $371,000 after buying an additional 53,154 shares during the period. Suncoast Equity Management purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $421,000. Northern Trust Corp purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $234,000. Finally, Squarepoint Ops LLC purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $223,000. Institutional investors and hedge funds own 0.62% of the company's stock.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
